Biography and Research Information
OverviewAI-generated summary
Lucas R. Johnson studies the impact of specific medical conditions and interventions on patient health outcomes. His research has investigated the role of P2Y12 receptor inhibitors in reducing hospitalization risk for sepsis in patients with chronic kidney disease (CKD). Johnson has also examined metabolic differences in circulating leukocytes among patients with CKD, specifically focusing on glycolysis levels. His work contributes to understanding the complex physiological changes associated with CKD and potential therapeutic strategies. Johnson has collaborated with Nishank Jain, Yasir Rahmatallah, and Dharmik Jadvani, all from the University of Arkansas for Medical Sciences, on shared publications. His current metrics include an h-index of 1, with a total of 3 publications and 1 citation.
Metrics
- h-index: 1
- Publications: 3
- Citations: 1
Selected Publications
-
Potent P2Y12 Receptor Inhibitors Reduce Risk for Hospitalization from Sepsis in Patients with CKD (2025)
-
Higher Glycolysis in Circulating Leukocytes in Patients with CKD (2024)
Collaboration Network
Top Collaborators
- Higher Glycolysis in Circulating Leukocytes in Patients with CKD
- Potent P2Y12 Receptor Inhibitors Reduce Risk for Hospitalization from Sepsis in Patients with CKD
- Higher Glycolysis in Circulating Leukocytes in Patients with CKD
- Higher Glycolysis in Circulating Leukocytes in Patients with CKD
- Higher Glycolysis in Circulating Leukocytes in Patients with CKD
- Potent P2Y12 Receptor Inhibitors Reduce Risk for Hospitalization from Sepsis in Patients with CKD
- Potent P2Y12 Receptor Inhibitors Reduce Risk for Hospitalization from Sepsis in Patients with CKD
- Potent P2Y12 Receptor Inhibitors Reduce Risk for Hospitalization from Sepsis in Patients with CKD
Similar Researchers
Based on overlapping research topics